A 52-week extension to the factorial study to evaluate the efficacy and safety of VAH631 (valsartan and hydrochlorothiazide combined [valsartan/hydrochlorothiazide]) and alone in essential hypertensive patients - long term study of VAH631 in patients with essential hypertension (extension from B1303 study).

Trial Profile

A 52-week extension to the factorial study to evaluate the efficacy and safety of VAH631 (valsartan and hydrochlorothiazide combined [valsartan/hydrochlorothiazide]) and alone in essential hypertensive patients - long term study of VAH631 in patients with essential hypertension (extension from B1303 study).

Completed
Phase of Trial: Phase III

Latest Information Update: 23 Feb 2017

At a glance

  • Drugs Hydrochlorothiazide (Primary) ; Valsartan (Primary) ; Valsartan/hydrochlorothiazide (Primary)
  • Indications Essential hypertension
  • Focus Adverse reactions
  • Sponsors Novartis
  • Most Recent Events

    • 13 Oct 2009 Actual end date (Jan 2007) added as reported by ClinicalTrials.gov.
    • 13 Oct 2009 Planned number of patients changed from 350 to 558 as reported by ClinicalTrials.gov.
    • 16 Oct 2007 Status changed from in progress to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top